olivLaw · US equity research
BioLineRx Ltd. BLRX
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
BioLineRx is an Israeli biopharmaceutical company developing therapies in oncology and rare diseases, with a focus on GLIX1 for glioblastoma and on motixafortide, whose first approved product, APHEXDA, now generates royalties. The company has sharply reduced costs after out-licensing its commercial rights, and its net loss fell from 60.6 million USD in 2023 to 2.0 million USD in 2025, while going-concern risk remains significant with liquidity estimated into the first half of 2027.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, BioLineRx Ltd. (BLRX) stock was 1.86 USD (−2.62% on the day), with market capitalisation 4.9 bn USD, beta 0.81, 52-week range 1.86–3.78 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 28.9
- oversold (≤ 30)
- Bollinger (20, 2)
- 1.86 – 2.25
- in the lower half of the band · %B 0.00 · band width 19.1%
- SMA 50 / 200
- 2.34 / 2.72
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.12 / -0.12
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −19.8% | −1.1% | −18.7 pp | — |
| 3 months | −31.6% | −0.5% | −31.2 pp | — |
| 6 months | −44.5% | +4.4% | −48.9 pp | — |
| Year to date | −32.9% | +12.3% | −45.2 pp | — |
| 1 year | −43.6% | +13.5% | −57.2 pp | +8.9% |
| 3 years | −97.1% | +76.4% | −173.6 pp | +15.7% |
| 5 years | −98.3% | +63.7% | −162.0 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | 0 | 0 | 4.8 m | 28.9 m | 1.2 m |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | +502.9% | −95.9% |
| Net income | -23.0 m | -25.4 m | -30.0 m | -27.1 m | -25.0 m | -60.6 m | -9.2 m | -2.0 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -0.12 | -0.04 | -0.03 | -0.06 | -0.01 | 0.00 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | -1,262.8% | -31.9% | -171.7% |
| Free cash flow | -24.4 m | -22.7 m | -23.2 m | -23.7 m | -26.4 m | -22.7 m | -43.9 m | -8.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 3.3 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 23.3 m USD
- Total assets
- 40.9 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.95x
- ROE
- -11.0%
- ROA
- -5.1%
- FCF margin
- -686.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 4.8 m | 28.9 m | 1.2 m | SEC (XBRL)· 23 Mar 2026verified |
| Cost of revenue | — | 0 | 0 | 3.7 m | 9.3 m | 230.0 k | SEC (XBRL)· 23 Mar 2026verified |
| Gross profit | — | 0 | 0 | 1.1 m | 19.7 m | 950.0 k | SEC (XBRL)· 23 Mar 2026verified |
| Research & development | 18.2 m | 19.5 m | 17.6 m | 12.5 m | 9.1 m | 8.1 m | SEC (XBRL)· 23 Mar 2026verified |
| Operating income | -22.9 m | -24.8 m | -29.2 m | -49.7 m | -20.4 m | -10.3 m | SEC (XBRL)· 23 Mar 2026verified |
| Depreciation & amortisation | 864.0 k | 660.0 k | 615.0 k | 583.0 k | 431.0 k | 495.0 k | SEC (XBRL)· 23 Mar 2026verified |
| EBITDA | -22.1 m ≈ | -24.1 m ≈ | -28.5 m ≈ | -49.1 m ≈ | -20.0 m ≈ | -9.8 m ≈ | SEC (XBRL)· 23 Mar 2026derived |
| Interest expense | 1.6 m | 1.0 m | 2.2 m | 2.2 m | 9.1 m | 1.3 m | SEC (XBRL)· 23 Mar 2026verified |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 23 Mar 2026verified |
| Net income | -30.0 m | -27.1 m | -25.0 m | -60.6 m | -9.2 m | -2.0 m | SEC (XBRL)· 23 Mar 2026verified |
| Diluted EPS | -0.12 | -0.04 | -0.03 | -0.06 | -0.01 | 0.00 | SEC (XBRL)· 23 Mar 2026verified |
| Weighted average diluted shares | — | — | — | 963.4 m | 1.2 bn | 2.5 bn | SEC (XBRL)· 23 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 16.8 m | 13.0 m | 10.6 m | 4.3 m | 10.4 m | 3.3 m | SEC (XBRL)· 23 Mar 2026verified |
| Inventories | — | — | 0 | 2.0 m | 3.1 m | 2.1 m | SEC (XBRL)· 23 Mar 2026verified |
| Current assets | 22.9 m | 57.4 m | 52.0 m | 47.2 m | 27.1 m | 23.7 m | SEC (XBRL)· 23 Mar 2026verified |
| Property, plant & equipment, net | 1.3 m | 952.0 k | 726.0 k | 473.0 k | 386.0 k | 160.0 k | SEC (XBRL)· 23 Mar 2026verified |
| Intangibles (excl. goodwill) | 21.7 m | 21.7 m | 21.9 m | 14.9 m | 10.4 m | 16.4 m | SEC (XBRL)· 23 Mar 2026verified |
| Total assets | 47.3 m | 81.4 m | 76.4 m | 63.9 m | 38.9 m | 40.9 m | SEC (XBRL)· 23 Mar 2026verified |
| Current liabilities | 10.6 m | 9.7 m | 10.7 m | 42.8 m | 15.4 m | 12.1 m | SEC (XBRL)· 23 Mar 2026verified |
| Total liabilities | 25.3 m | 13.3 m | 25.5 m | 50.7 m | 25.4 m | 17.6 m | SEC (XBRL)· 23 Mar 2026verified |
| Equity | 22.0 m | 68.1 m | 50.8 m | 13.2 m | 13.5 m | 23.3 m | SEC (XBRL)· 23 Mar 2026verified |
| Shares outstanding at year end | 349.2 m | 715.2 m | 923.0 m | 1.1 bn | — | — | SEC (XBRL)· 26 Mar 2024verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.2 m | -23.6 m | -26.2 m | -22.6 m | -43.9 m | -8.1 m | SEC (XBRL)· 23 Mar 2026verified |
| Capex | 0 | 97.0 k | 131.0 k | 116.0 k | 53.0 k | 25.0 k | SEC (XBRL)· 23 Mar 2026verified |
| Free cash flow | -23.2 m ≈ | -23.7 m ≈ | -26.4 m ≈ | -22.7 m ≈ | -43.9 m ≈ | -8.1 m ≈ | SEC (XBRL)· 23 Mar 2026derived |
| Investing cash flow | 16.7 m | -38.2 m | 4.0 m | 1.4 m | 29.4 m | -8.5 m | SEC (XBRL)· 23 Mar 2026verified |
| Financing cash flow | 17.9 m | 57.7 m | 20.4 m | 15.1 m | 20.7 m | 8.9 m | SEC (XBRL)· 23 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 4.9 bn USD
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -171.7% | 21 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -8.0x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 2.0x | 96 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -0.2% | 0 (on a fixed band) | 33% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet38/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial21/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
BioLineRx Ltd (BLRX). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 1.2 m USD in 2025; YoY growth -95.9%; net margin -171.7%; ROE -12.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 2.0x
What contradicts it
- Net margin: -171.7%
- Interest coverage: -8.0x
- FCF yield: -0.2%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| BLRXBioLineRx Ltd | 4.9 bn | — | -12.8% | -171.7% | −95.9% | −44% / −97% |
| HRMYHarmony Biosciences Holdings, Inc. | 2.0 bn | 11.4 | 18.7% | 18.1% | +21.5% | −2% / +18% |
| OMEROmeros Corp | 1.3 bn | 10.5 | — | — | −34.0% | +88% / +730% |
| VSTMVerastem, Inc. | 892.0 m | — | -471.2% | -231.6% | +209.1% | −7% / +43% |
| COLLCollegium Pharmaceutical, Inc. | 770.6 m | 19.1 | 17.6% | 5.9% | +23.6% | −49% / −8% |
| IBOImpact BioMedical, INC. | 442.1 m | 560.3 | 371.3% | 2,254.3% | unavailable | −27% / unavailable |
| KMDAKamada Ltd | 428.0 m | 21.2 | 7.6% | 11.2% | +12.1% | +11% / +57% |
1- and 3-year price returns: for BLRX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 23 Mar 2026; since then the company filed 6-K (23 Oct 2026), 6-K (24 Sept 2026), 6-K (10 Sept 2026), 6-K (31 Aug 2026), 6-K (28 Aug 2026).
In brief
BioLineRx is an Israeli biopharmaceutical company developing therapies in oncology and rare diseases, with a focus on GLIX1 for glioblastoma and on motixafortide, whose first approved product, APHEXDA, now generates royalties. The company has sharply reduced costs after out-licensing its commercial rights, and its net loss fell from 60.6 million USD in 2023 to 2.0 million USD in 2025, while going-concern risk remains significant with liquidity estimated into the first half of 2027.
SWOT
Strengths
- The company has an FDA-approved product generating royalties, plus a pipeline in oncology and rare diseases with retained rights across multiple indications 1.
- Transaction structures with modest upfront payments and success-based components limit the company's financial exposure 1.
- The net loss narrowed sharply after the reorganization of activities, indicating tighter cost discipline 1.
Weaknesses
- The company carries a very large accumulated deficit, has not reached profitability, and has so far earned limited revenue 1.
- Liquidity is considered sufficient only into the first half of 2027, creating pressure for new financing 1.
- A secured loan exists, and a default could expose some or all assets to forfeiture 1.
Opportunities
- If GLIX1 clinical data are favorable, the glioblastoma market could become a major opportunity for the company 1.
- Royalties and milestones from the Ayrmid and Gloria agreements could fund development of other assets in the portfolio 1.
- Expanding motixafortide into solid tumor indications outside Asia could create additional shareholder value 1.
Threats
- Delays and uncertainty in the China program could reduce revenue expected from the Gloria partnership 1.
- If clinical studies fail or are delayed, development of the assets could be suspended or abandoned 1.
- Pricing and reimbursement pressures in the pharmaceutical sector could limit revenue from approved products 1.
Risks
- Going concernhigh
Management concluded there is substantial doubt about the company's ability to continue as a going concern, which could prevent it from obtaining new financing on reasonable terms 1.
- Limited liquidityhigh
Existing resources are projected to cover capital needs only into the first half of 2027, and future financing is not assured 1.
- Asset-secured loanhigh
If the company defaults on its obligations to its lender, some or all of its assets could be subject to forfeiture 1.
- Dependence on partnersmedium
Revenue and development timing depend on Ayrmid and Gloria, and difficulties on their side could directly affect the company's cash flows 1.
- Clinical and regulatory riskmedium
Clinical trials are costly and uncertain, and approvals may be delayed or not obtained, affecting commercialization 1.
Investment thesis
What would need to be true (bull case)
- If GLIX1 shows clinical benefit in glioblastoma, the company could address a market estimated in billions of dollars supported by a significant unmet medical need 1.
- The transaction structure and lower spending could allow the company to extend its funding runway if these conditions hold 1.
- Royalties from APHEXDA and possible milestones could become a steadier income source as partner commercialization advances 1.
What would break the thesis
- The company has not reached profitability, and management has flagged going-concern uncertainty, which could force shareholder dilution 1.
- If partners run into difficulties or the China program stays stalled, expected revenue could be delayed or reduced 1.
- Debt secured by assets could limit financial flexibility if cash reserves prove insufficient 1.
What to watch
- Start of the GLIX1 Phase 1/2 studyQ1 2026
- Phase 1 data from the GLIX1 studyH1 2027
- Interim futility analysis in the PDAC study2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 23 Mar 2026; since then the company filed 6-K (23 Oct 2026), 6-K (24 Sept 2026), 6-K (10 Sept 2026), 6-K (31 Aug 2026), 6-K (28 Aug 2026).
The business
BioLineRx Ltd. is a biopharmaceutical company organized in Israel, listed on Nasdaq and the TASE under the symbol BLRX, pursuing therapies for patients in oncology and rare diseases 1. Its first approved product, APHEXDA (motixafortide), received FDA approval in September 2023 for mobilizing hematopoietic stem cells in patients with multiple myeloma 1. Since November 2024, the company has out-licensed global rights other than Asia to Ayrmid, while Asian rights sit with partner Gloria, so BioLineRx now focuses on development in Israel and on future royalties 1.
The company's growth strategy rests on in-licensing assets in oncology and rare diseases, using transactions with modest upfront payments and success-based components that limit financial exposure 1. The company says development of its assets is supported by royalties and milestones from existing partnerships, an objective that still depends on clinical success and contractual terms 1.
In September 2025 BioLineRx entered a collaboration with Hemispherian for GLIX1, an oral small molecule for glioblastoma and other solid tumors, held 40% through the entity Tetragon 1. A Phase 1/2 study was expected to begin in Q1 2026, after the FDA cleared the IND in August 2025 1.
Segments
Motixafortide (APHEXDA)
Motixafortide is a peptide that blocks CXCR4 and is approved for stem cell mobilization in multiple myeloma patients, with royalties flowing from Ayrmid's commercialization 1. The company retains rights for solid tumor indications outside Asia, including pancreatic cancer, where an investigator-initiated Phase 2b study sponsored by Columbia University continues at minimal cost to the company 1.
GLIX1
GLIX1 is an oral agent developed for glioblastoma, designed to restore TET2 activity and address DNA repair in cancer cells 1. Plans call for Phase 1 data in H1 2027 and Phase 2 data in H1 2028, and the company says development could extend to other cancers 1.
Rare diseases and pipeline
The company tested motixafortide in sickle cell disease in Phase 1 studies with Washington University and St. Jude Children's Research Hospital, and these were continued under the Ayrmid license 1. The planned pivotal study in China under the Gloria license is not advancing on schedule, and its start is unclear 1.
Market context
The company estimates the total addressable market for newly diagnosed and recurrent glioblastoma in the U.S., Germany, UK, France, Italy and Spain will reach about 3.7 billion USD by 2030 1. Expected annual incidence is roughly 18,500 patients in the U.S. and 13,400 across the EU5 by 2030 1.
The current standard of care for glioblastoma, set in 2005, gives only marginal survival gains, mainly in the roughly 30% of patients with a methylated MGMT promoter, and no standard exists for recurrent disease, which the company frames as a significant unmet need 1.
Trends
- Unmet need in glioblastomatailwind
A two-decade-old standard of care offers limited gains and recurrent disease has no established standard, creating room for new therapies if clinical data confirm benefit 1.
- Aging populationtailwind
The company notes glioblastoma incidence rises with the aging global population, which could expand the market if the trend holds 1.
- Reliance on partners and regulatorsheadwind
Future revenue depends on Ayrmid and Gloria royalties, and delays in China show that timelines can be shaped by external partners and authorities 1.
- Costs reduced by shutting down commercial activitymixed
Closing U.S. commercialization cut sales and marketing spending, which could keep cash burn lower but limits near-term revenue generated in-house 1.
Competitive position
The supplied source does not detail competitors in the glioblastoma market or in stem cell mobilization. The company does note that competing therapies that are more effective, safer or less expensive could negatively affect its prospects, without naming specific rivals 1.
For motixafortide, competition includes existing treatments for stem cell mobilization, against which the company compares its trials, though the source does not identify specific competing products for detailed analysis 1.
- Ayrmid Pharma Ltd.
Partner commercializing APHEXDA globally outside Asia and paying royalties to BioLineRx 1.
- Gloria
Partner holding motixafortide rights in Asia, with potential milestone and royalty payments to the company 1.
- Regeneron
Supports alongside the company the investigator-initiated Phase 2b pancreatic cancer study 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)23 Oct 2026
- Current report (foreign issuer)24 Sept 2026
- Current report (foreign issuer)10 Sept 2026
- Current report (foreign issuer)31 Aug 2026
- Current report (foreign issuer)31 Aug 2026
- Current report (foreign issuer)28 Aug 2026
- Current report (foreign issuer)18 Aug 2026
- Current report (foreign issuer)08 Jul 2026
- Current report (foreign issuer)27 May 2026
- Current report (foreign issuer)22 May 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / BioLineRx Ltd. · 23 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.